Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samer Abbas

Interventional Cardiology East Chicago, IN Medical Doctor

NPI 1568481182 CMS profile 161857

4320 Fir St, Ste 320, East Chicago, IN 46312

Open in the dashboard

General payments

$395,499

1,571 records reported · program years 2019–2025

Research payments

$3,160

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$229,240 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Samer Abbas of East Chicago, IN is reported in the CMS Open Payments database as having received $395,499 across 1,571 general payments and $3,160 in research payments paid to them. Separately, studies naming them as principal investigator received $229,240 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $85,685 265
2024 General $61,700 235
2023 General $67,484 235
2022 General $98,289 292
2021 General $23,205 179
2020 General $19,604 83
2019 General $39,533 282
2019 Research $3,160 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samer Abbas
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Samer Abbas were reported at $85,685. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Samer Abbas Interventional Cardiology median Middle half National median
2019 $39,533 $1,097 $329–$3,048 $163
2020 $19,604 $473 $161–$1,480 $114
2021 $23,205 $677 $233–$1,827 $132
2022 $98,289 $978 $333–$2,724 $149
2023 $67,484 $1,136 $382–$2,986 $160
2024 $61,700 $1,181 $395–$3,326 $164
2025 $85,685 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $233,429 477 payments
  2. Edwards Lifesciences Corporation $46,170 216 payments
  3. Medtronic Vascular, Inc. $32,927 59 payments
  4. Boston Scientific Corporation $23,713 109 payments
  5. Cardiovascular Systems Inc. $11,685 38 payments
  6. Biosense Webster, Inc. $8,057 37 payments
  7. Abbott Laboratories $5,374 73 payments
  8. Biotronik Inc. $5,042 20 payments
  9. Cardiva Medical, Inc. $2,634 9 payments
  10. Opsens Inc. $2,291 10 payments
  11. Other $24,177 523 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $199,014 63 payments
  2. Food and Beverage $67,681 1,243 payments
  3. Consulting Fee $62,806 18 payments
  4. Travel and Lodging $54,695 238 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $11,000 3 payments
  6. Entertainment $263 5 payments
  7. Education $40 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $207,553 366 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $18,322 81 payments
  3. IN.PACT Admiral $17,542 17 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $14,235 16 payments
  5. General - Vascular Access $11,875 5 payments
  6. HawkOne $11,744 20 payments
  7. Diamondback Coronary $9,967 13 payments
  8. Diamondback Peripheral $9,886 15 payments
  9. TurboHawk $9,345 3 payments
  10. General - Therapies $7,278 11 payments
  11. Other $109,696 1,105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $3,160 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

4,710

Median for Interventional Cardiology: 2,236

Drug cost

$887,492

Median for Interventional Cardiology: $380,412

Branded share of claims

30.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 216 $319,166
Eliquis Apixaban Brand 175 $213,666
Repatha Sureclick Evolocumab Brand 164 $134,278
Farxiga Dapagliflozin Propanediol Brand 62 $77,091
Xarelto Rivaroxaban Brand 36 $51,500
Brilinta Ticagrelor Brand 41 $45,942
Ranolazine Er Ranolazine Brand 49 $5,888
Clopidogrel Clopidogrel Bisulfate Brand 548 $5,827
Atorvastatin Calcium Generic 491 $3,554
Metoprolol Succinate Generic 289 $2,815

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$251,107

Medicare's payments for the services billed

Medicare patients

986

Average age 77

Services billed

2,321

497 women, 489 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 53%
Atrial fibrillation 41%
Heart failure 40%
Diabetes 39%
Chronic kidney disease 34%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$221 — —
Repatha
$100 164 —
ENTRESTO
$71 216 —
JARDIANCE
$60 — —
ELIQUIS
$20 175 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

1,572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record